Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.15% to $462.13 Friday, on what proved to be an all-around grim trading ...

Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...

This was the stock's third consecutive day of losses.

Vertex Pharmaceuticals (VRTX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX) will report quarterly earnings of $4.24 per share in its upcoming release, pointing to a year-over-year increase of 133.1%. It is ...

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

Some Boston public school students are spending their summer vacations learning and working at a global biotech company.

Vertex Pharmaceuticals is trying to replicate its winning cystic fibrosis formula in other areas. These efforts could yield even better financial results than its potential gene-editing therapy.

Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and ...